Management Team

David J. Mazzo, PhD

President and Chief Executive Officer

Dr. Mazzo is the President and CEO of Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. The Company’s primary technology platform is based on the use of CD34+/CXCR4+ cells for ischemic repair in a variety of indications including critical limb ischemia, coronary microvascular disfunction and no-option refractory disabling angina (NORDA). Dr. Mazzo is a pharmaceutical executive and strategic leader with broad experience in both large and small companies gained from working in a variety of multi-cultural and multi-lingual environments in the USA, Canada, Europe and Asia. He is recognized for his exceptional strategic, scientific and regulatory expertise, upon which he has amassed a track record of >35 years of successful global product development, registration and launch. Dr. Mazzo is a demonstrated change leader uniquely adept at integrating disparate groups, turning around dysfunctional organizations and driving working groups to new levels of performance and achievement.

Dr. Mazzo is a seasoned public and private company director having served on the boards of all the companies for which he was CEO plus Essex Chimie AG (EU subsidiary of Schering-Plough), Avanir Pharmaceuticals, EyePoint Pharmaceuticals and Seneca Biopharma. For Avanir (NASDAQ: AVNR), he served from 2005 – 2015 (until the sale of Avanir to Otsuka) and was, at various times, a member of the Executive committee of the Board, Science committee, Audit committee and/or Governance committee. From 2008 to 2015, he served as chairman of the Compensation committee. For EyePoint (NASDAQ: EYPT), Dr. Mazzo has also served since 2005 and has been, at various times, a member of the Science, Audit and/or Governance committees. He has chaired the Compensation committee since 2005 and was Chairman of the Board from 2007 - 2018. For Seneca (NASDAQ: SNCA), Dr. Mazzo has served since 2019. He is a member both the Compensation and Nominating & Governance Committees.

Dr. Mazzo has spent his entire career within the pharmaceutical industry, rising quickly from the laboratory to occupy positions of increasing executive responsibility with Merck, Baxter, Rhône-Poulenc Rorer, Hoechst Marion Roussel and Schering-Plough before becoming CEO of Chugai USA (private) followed by Aeterna Zentaris (public), Regado Biosciences (which he took public) and Caladrius Biosciences (public). The diversity of his assignments has resulted in an expertise across all therapeutic areas as well as the whole of the drug development process from Discovery to Development to Product Commercialization.

Dr. Mazzo earned his Ph.D. in Analytical Chemistry as well as an M.S. in Chemistry at the University of Massachusetts (Amherst). He also holds dual degrees [B.S. in Chemistry and B.A. in Honors (Interdisciplinary Humanities)] from Villanova University. He complemented his American education as a Research Fellow at the Ecole Polytechnique Fédérale de Lausanne in Switzerland.

Douglas W. Losordo, MD, FACC, FAHA

Executive Vice President, Global Head of Research and Development, Chief Medical Officer

Dr. Losordo is Executive Vice President, Global Head of Research and Development and Chief Medical Officer of Caladrius Biosciences and served from 2006 to 2013 as a member of the Scientific Advisory Board of Caladrius. Prior to joining the company in 2013, Dr. Losordo served as Vice President, New Therapies Development, Regenerative Medicine and Baxter Ventures at Baxter International from 2011 to 2013. He is an adjunct professor of medicine at Northwestern University in Chicago, Illinois. From 2006 through 2011, Dr. Losordo was the director of the Feinberg Cardiovascular Research Institute and the Eileen M. Foell Professor of Heart Research at Northwestern University’s School of Medicine and director of the Program in Cardiovascular Regenerative Medicine at Northwestern Memorial Hospital. Previously he was Professor of Medicine at Tufts University School of Medicine and Chief of Cardiovascular Research at St. Elizabeth’s Medical Center in Boston. He is board-certified in internal medicine, cardiovascular disease, and interventional cardiology. Dr. Losordo’s major research interests encompass angiogenesis/vasculogenesis, progenitor/adult stem cells, tissue repair/regeneration, and vascular biology. He received his M.D. from the University of Vermont.

Dr. Losordo has engaged in career-long efforts to develop regenerative medicine therapeutics. As a scientist he obtained over $35 million in National Institutes of Health funding, for discovering and developing new therapeutic concepts in the laboratory, providing the basis for clinical studies. He has led first in human studies in multiple gene and adult stem cell therapies in patients with cardiovascular diseases, including therapies now in Phase 3 testing. He is a highly sought after speaker, having given over 200 international lectures. He has served as an associate editor of Circulation Research, the basic science journal of the American Heart Association and serves on the editorial boards of a number of scientific journals.

Todd Girolamo, JD

Senior Vice President, General Counsel and Corporate Secretary

Todd Girolamo joined Caladrius in 2011. He is a seasoned attorney specializing in health-related products and businesses. As a member of the Caladrius senior management team, Mr. Girolamo has been responsible for managing all legal aspects of the Company’s research and development pipeline, from preclinical research to multinational pivotal clinical trials, including academic and corporate collaborations. He has been responsible for the Company’s licensing activities; the strategy, maintenance and prosecution of the Company’s extensive global patent estate; and the management of all litigation involving the Company and its subsidiaries.

Mr. Girolamo began his legal career as an associate at Cahill Gordon & Reindel, and he concluded his tenure in private practice at Reid & Priest, where he gained expertise as a general commercial litigator practicing in the areas of intellectual property, securities law, employment law and bankruptcy. In addition to over a decade of experience as both corporate counsel and private practitioner, Mr. Girolamo spent 12 years on Wall Street where he specialized in therapeutic healthcare equity securities at Oppenheimer & Co., CIBC World Markets, Leerink Swann & Company and Summer Street Research Partners.

Mr. Girolamo received a Bachelor of Arts from Harvard College, Juris Doctor from the University of Pennsylvania Law School and Master of Business Administration from Columbia Business School.

Gail Holler

Vice President, Human Resources

Gail Holler joined Caladrius Biosciences in January 2019 as VP of Human Resources. Gail brings over 30 years of HR experience in organizational strategy, career development, recruitment, benefits and compensation. She has supported both large and small organizations in the pharmaceutical and biotech industries. Gail will be responsible for all generalist activities and will serve as the management liaison to the Compensation Committee of the Board of Directors.

Ms. Holler's background includes developing and leading global teams. She has driven organizational transformation efforts at Innophos Inc., a global specialty chemical company as VP of HR where she planned and developed organizational design and integration activity for mergers and acquisitions. In addition, she served as management liaison to the Compensation and Nominating and Governance Committees. Prior to Innophos, Ms. Holler served as Director of Organizational Effectiveness at Tata Consultancy Services where she was responsible for on-boarding, training and deployment of talent for the organization. Prior to that, Ms. Holler served as VP of HR at LifeCell Corporation where she established the HR organization and led the growth of the organization through succession planning, career development and recruitment of key talent. Prior to joining LifeCell, she was with Sanofi Aventis (and legacy companies) for 14 years where she held increasingly more responsible positions in global HR generalist capacities including HR Director for Global Drug Development and VP of HR, Global Dermatology.

Ms. Holler received a BA from the University of Delaware.

Gregory S. Berkin

Vice President of IT and Cybersecurity and Chief Information Officer

M.S. (computer science/computer forensics) Fairleigh Dickinson University

Greg Berkin joined Caladrius in January 2015. Since that time, Greg has been responsible for transforming external IT support into an internal team working as a highly-efficient operating unit across all five Caladrius and PCT sites. He also manages all groups within IT: Networking, PC, Cybersecurity, Applications, Business Solutions, and Telecom.

Before joining Caladrius, Greg held director and management roles in IT at other biotech companies including Regado Biosciences, Aeterna Zentaris, and Chugai Pharma USA.

Greg has 25 years in the technical profession with 20 years of unparalleled managerial experience, specializing in production systems, network engineering, facility operations, project management, hybrid cloud-computing, cybersecurity, and M&A activities.

John D. Menditto

Vice President, Investor Relations and Corporate Communications

John D. Menditto joined Caladrius Biosciences in 2017. He is an experienced corporate communications and investor relations professional. John’s stakeholder communications work is done in partnership with our Finance, Clinical, Regulatory, Legal, Human Resource and Executive teams. He reports directly to both the Chief Executive Officer and the Chief Financial Officer.

Mr. Menditto has over 25 years of experience and specialization, particularly, in the areas of financial modeling, Regulation FD, corporate governance, investor targeting and capital raising. He has held senior roles at several healthcare and life science companies including Novartis Corporation, Medco Health Solutions and Argos Therapeutics. John has also spent a number of years as a senior communications consultant with The Imagination Group, Makovsky & Co. and MWWPR.

John is a former IR Magazine and PRSA/Big Apple award winner for his work in investor and corporate communications. He holds degrees in public relations and finance from Susquehanna University in Selinsgrove, Pennsylvania.